<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4347">
  <stage>Registered</stage>
  <submitdate>6/12/2013</submitdate>
  <approvaldate>6/12/2013</approvaldate>
  <nctid>NCT02008357</nctid>
  <trial_identification>
    <studytitle>Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss</studytitle>
    <scientifictitle>Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)</scientifictitle>
    <utrn />
    <trialacronym>A4</trialacronym>
    <secondaryid>H8A-MC-LZAZ</secondaryid>
    <secondaryid>15275</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cognition Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Learning disabilities</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Solanezumab
Treatment: drugs - Placebo

Experimental: Solanezumab - Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.

Placebo Comparator: Placebo - Placebo IV every 4 weeks for 240 weeks.


Treatment: drugs: Solanezumab
Administered IV

Treatment: drugs: Placebo
Administered IV

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline of the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC) to Week 240</outcome>
      <timepoint>Baseline, Week 240</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Cognitive Function Index (CFI) to Week 240</outcome>
      <timepoint>Baseline, Week 240</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Alzheimer's Disease Cooperative StudyActivities Daily LivingPrevention Questionnaire (ADCS-ADL-Prevention Questionnaire) Score to Week 240</outcome>
      <timepoint>Baseline, Week 240</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Mean Composite Standardized Uptake Value Ratio (SUVr) to Week 240</outcome>
      <timepoint>Baseline, Week 240</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Cerebrospinal Fluid (CSF) Tau Biomarkers to Week 240</outcome>
      <timepoint>Baseline, 240 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline of CSF Concentrations of Amyloid Beta (Abeta) to Week 240</outcome>
      <timepoint>Baseline, 240 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI) to Week 240</outcome>
      <timepoint>Baseline, Week 240</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30

          -  Has a global Clinical Dementia Rating (CDR) scale score at screening of 0

          -  Has a Logical Memory II score at screening of 6 to 18

          -  Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain
             amyloid pathology at screening

          -  Has a study partner that is willing to participate as a source of information and has
             at least weekly contact with the participant (contact can be in-person, via telephone
             or electronic communication)</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at
             screening or baseline

          -  Lacks good venous access, such that intravenous drug delivery or multiple blood draws
             would be precluded

          -  Has current serious or unstable illness including cardiovascular, hepatic, renal,
             gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic,
             or hematologic disease or other conditions that, in the investigator's opinion, could
             interfere with the analyses of safety and efficacy in this study

          -  Has had a history within the last 5 years of a serious infectious disease affecting
             the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma
             resulting in protracted loss of consciousness

          -  Has had a history within the last 5 years of a primary or recurrent malignant disease
             with the exception of any in situ cancer that was appropriately treated and is being
             appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or
             in situ prostate cancer with normal prostate-specific antigen post-treatment

          -  Has a known history of human immunodeficiency virus (HIV), clinically significant
             multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions
             (including, but not limited to, erythema multiforme major, linear immunoglobulin A
             dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)

          -  Is clinically judged by the investigator to be at serious risk for suicide

          -  Has a history within the past 2 years of major depression or bipolar disorder as
             defined by the most current version of the Diagnostic and Statistical Manual of Mental
             Disorders (DSM)

          -  Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as
             defined by the most current version of the DSM</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville</hospital>
    <postcode>3010 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Bunkyo-ku</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Alzheimer's Therapeutic Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test whether an investigational drug called solanezumab can
      slow the progression of memory problems associated with brain amyloid (protein that forms
      plaques in the brains of people with Alzheimer Disease [AD]).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02008357</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or</name>
      <address />
      <phone>1-317-615-4559</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>